Grant Awarded to BU-Led Team Targeting Early Lung Cancer Detection | Chobanian & Avedisian School of Medicine

Boston University’s Chobanian & Avedisian School of Medicine has been awarded a $3.4 million five-year grant by the NIH’s National Cancer Institute. This grant aims to enhance the management of early-stage lung cancer through innovative research. The project, led by Joshua D. Campbell, Ph.D., focuses on developing biomarkers to improve early detection and treatment, reducing false-negative rates and minimizing unnecessary procedures.

The team, which includes collaborators from institutions like Roswell Park Comprehensive Cancer Center, the University of Colorado Anschutz, and UCLA, utilizes advanced technologies such as robotic-assisted biopsies, AI-driven image analysis, and spatial transcriptomics. These tools enable more accurate diagnostics and personalized treatment strategies. The award underscores the significance of integrating cutting-edge medical techniques to address a critical health challenge, ensuring timely intervention for aggressive tumors while preserving healthy individuals.

This breakthrough is expected to change lung cancer management, improving patient outcomes and setting a precedent for future cancer research. The grant highlights the importance of collaborative efforts in advancing medical science and patient care.

News is prepared from public university announcements for general guidance. Policies change frequently; confirm current details with each university admissions office.